Fractional CO2 (FxCO2) Laser Therapy Combined with Erythromycin Ophthalmic Ointment–Based Moist Wound Healing for Facial Pigmented Scars: A Retrospective Observational Study Authors: Yue Jin, Qingmei Jin, Jiahui Zhi, Zhenlong Zheng, Chenglong Jin Published: 2026 ABSTRACT BackgroundTreatment of pigmented scars requires simultaneous scar remodeling, pigment regulation, and prevention of postinflammatory hyperpigmentation (PIH).AimTo evaluate the efficacy and safety of fractional CO2 laser therapy combined with moist healing for pigmented scars.Patients/MethodsThis retrospective self-controlled study included 34 patients with facial pigmentation scars treated with fractional CO2 laser therapy. Postoperative wound care consisted of a standardized moist healing regimen using topical erythromycin ophthalmic ointment. Treatment efficacy was assessed at baseline and 3 months after the final treatment using the Patient and Observer Scar Assessment Scale (POSAS) and a four-grade efficacy scale. Treatment parameters, number of sessions, and adverse reactions were recorded.ResultsScar appearance significantly improved after a mean of 5.44 ± 1.80 treatments. The total POSAS score decreased from 83.97 ± 4.16 points before treatment to 33.56 ± 3.27 (P < 0.0001). The overall effective rate was 100.00%. Adverse reactions, mainly transient erythema and edema, were mild. Mild PIH occurred in three patients and resolved spontaneously within 3 months. No serious adverse events, including infection, permanent depigmentation, or scar aggravation, were observed.ConclusionFractional CO2 laser therapy combined with moist healing effectively improves facial pigmented scars with a favorable safety profile. Introduction Pigmented scars are common sequelae of skin lesion healing, and their clinical manifestation includes both morphological abnormalities (eg, hyperplasia and depressions) and hyperpigmentation. The occurrence of these scars in exposed areas such as the face can seriously affect the appearance and mental health of patients, prompting urgent treatment. The core goal of clinical treatment is to simultaneously achieve morphological remodeling of scars and normalization of pigment metabolism. However, existing treatments, especially laser therapy for traumatic scars, can induce inflammatory responses while destroying scar tissue to initiate remodeling, thereby leading to postinflammatory hyperpigmentation (PIH), which is a common complication of pigmentation treatment. By generating tiny thermal damage bands, fractional CO2 laser therapy can accurately vaporize scar tissue and deeply stimulate dermal collagen regeneration and remodeling, providing an effective method for improving scar morphology. However, the wound healing process after laser therapy is directly related to the final efficacy and the occurrence of complications. Traditional postoperative care (cold compresses) focuses on reducing inflammation during the acute phase and has limited ability to actively regulate the wound microenvironment. On the contrary, maintaining a moderately moist wound environment can promote the release of growth factors, accelerate keratinocyte migration, and effectively relieve pain and inflammation. These findings provide a theoretical basis for optimizing wound management after laser therapy and preventing PIH. Several laser treatment modalities are used for scar and pigment management based on the dominant clinical feature. Pulsed dye laser and ablative fractional laser therapies have shown benefits in scar remodeling.1 In addition, studies have supported the use of moist wound healing after fractional CO2 laser therapy and integrated periprocedural skincare.2,3 Pigment-targeting lasers have been used for PIH treatment; however, the evidence remains limited, and laser-induced or exacerbated PIH is a recognized concern. This concern is particularly relevant in patients with darker skin types.4 Therefore, in this study, we used individualized ablative fractional CO2 laser therapy to address both superficial and deeper scar components and combined it with standardized moist wound healing to support re-epithelialization and postoperative tolerance. This study was designed to extend established therapeutic principles into this specific real-world clinical setting. Based on these findings, our hospital has adopted a treatment strategy that combines fractional CO2 laser therapy with moist wound healing in clinical practice. The theoretical basis of this strategy is that laser therapy can improve scar morphology, moist healing can optimize the healing environment of the wound, and their combination can produce synergistic effects. This retrospective study aimed to evaluate the clinical efficacy and safety of fractional CO2 laser therapy combined with moist healing for the treatment of facial pigmented scars. We reviewed the clinical data of 34 patients who underwent fractional CO2 laser therapy combined with moist healing for pigmented scars. The effects of this treatment strategy on the appearance of pigmented scars (eg, vascularity, color, and thickness) and the subjective feelings of patients (eg, pain and itching) were evaluated, and postoperative adverse reactions were assessed. Materials and Methods Ethics Statement This study followed the ethical standards established in the 1964 Declaration of Helsinki and was approved by the Medical Ethics and Human Research Committee of Suzhou Mylike Cosmetic Hospital (Approval No.: 2025002). All patients signed an informed consent form before treatment. Participants This retrospective study included 34 patients with facial pigmented scars who were treated with fractional laser therapy combined with moist healing at Suzhou Mylike Cosmetic Hospital between September 2021 and June 2025. The inclusion criteria were as follows: (1) individuals who met the diagnostic criteria for pigmented scars according to the Expert Consensus on Clinical Scar Prevention and Control in China; (2) individuals who had not received any treatment for the scars within the past 3 months; and (3) individuals who had no contraindications or allergy to the treatment regimen. The exclusion criteria were as follows: (1) individuals who do not meet the diagnostic criteria for pigmented scars; (2) pregnant/lactating women or individuals with scar constitution; (3) individuals with allergy to lidocaine, erythromycin, or laser treatment–related components; and (4) individuals who did not sign the informed consent form or were confused and unable to cooperate with treatment. Instruments and Materials The AcuPulse laser system (Lumenis, USA) was used for fractional CO2 laser therapy. A dermatoscope (Dr. Camscope, South Korea) and digital camera (Canon EOS 7D) were used for skin assessment. Standardized digital photographs were acquired using the ISEMECO skin imaging analyzer. Furthermore, 5% compound lidocaine cream (Tongfang Pharmaceutical Group Co., Ltd.) was used to anesthetize the skin, and erythromycin ophthalmic ointment (Chenxin Fodu Pharmaceutical Co., Ltd.) was used for moist healing. Therapeutic Method After the patients cleaned their faces, a photograph of the scar area was captured, and the baseline scar condition was assessed using a dermatoscope. The treatment site was anesthetized with 5% compound lidocaine cream for 1 hour. Subsequently, the skin was cleaned with normal saline and disinfected with iodophor. An individualized fractional CO2 laser therapy protocol (AcuPulse system) was used for different types of scar features. Based on the specific pathological characteristics (eg, hyperplasia thickness, depression depth, and color distention degree) and clinical manifestations of the scar, artificial fractional, deep, and superficial modes were flexibly used for targeted single-use or multi-mode combined application, and the parameters were individualized as shown below. Artificial fractional mode: The continuous wave (super pulse) mode was adopted, with a power of 1–3 W. Each hole was treated for 1–3 seconds, and scar tissue was vaporized intermittently.Deep mode (deep repair): An energy range of 10-20 mJ/cm2, a spot size of 5–10 mm, and a coverage (density) of 5% were used to stimulate deep collagen remodeling of the dermis.Superficial mode (superficial modification): An energy range of 90–170 mJ/cm2, a spot size of 6–10 mm, and a coverage of 40% were used to reduce superficial pigmentation and improve skin texture. Artificial fractional mode: The continuous wave (super pulse) mode was adopted, with a power of 1–3 W. Each hole was treated for 1–3 seconds, and scar tissue was vaporized intermittently. Artificial fractional mode: The continuous wave (super pulse) mode was adopted, with a power of 1–3 W. Each hole was treated for 1–3 seconds, and scar tissue was vaporized intermittently. Deep mode (deep repair): An energy range of 10-20 mJ/cm2, a spot size of 5–10 mm, and a coverage (density) of 5% were used to stimulate deep collagen remodeling of the dermis. Deep mode (deep repair): An energy range of 10-20 mJ/cm2, a spot size of 5–10 mm, and a coverage (density) of 5% were used to stimulate deep collagen remodeling of the dermis. Superficial mode (superficial modification): An energy range of 90–170 mJ/cm2, a spot size of 6–10 mm, and a coverage of 40% were used to reduce superficial pigmentation and improve skin texture. Superficial mode (superficial modification): An energy range of 90–170 mJ/cm2, a spot size of 6–10 mm, and a coverage of 40% were used to reduce superficial pigmentation and improve skin texture. After treatment, erythromycin ophthalmic ointment was applied 4–6 times a day, and all patients were instructed to strictly protect themselves from the sun. The interval between treatments was 3 months. Treatment efficacy was assessed based on the follow-up data collected within 3 months after the final treatment. Clinical Efficacy Evaluation and Data Extraction The clinical data of all patients who met the inclusion criteria were systematically extracted from the electronic medical record system of the hospital for evaluation. Data Collection The following data were independently extracted and cross-checked by two investigators. Baseline data: age and sex Scar characteristics: etiology (eg, postoperative, trauma, and acne), disease course, location, scar type (depressed, hypertrophic, and mixed), and depth of scar basal before treatment Treatment-related parameters: the laser mode (artificial fraction, deep, and superficial) and specific energy parameters used for each treatment, the total number of treatments, the time between treatments, and the type of drug used for postoperative moist healing Follow-up data: Total follow-up duration Efficacy and Safety Assessment Treatment efficacy was assessed based on data collected before treatment (baseline) and follow-up data obtained within 3 months after the last treatment session. Main efficacy indicators: The Patient and Observer Scar Assessment Scale (POSAS) (Table 1) was used to assess efficacy. POSAS is a core assessment tool that consists of two parts as follows:Table 1Scar Assessment Using the Patient and Observer Scar Assessment Scale (POSAS)Table summarizing the Patient and Observer Scar Assessment Scale (POSAS), including six observer-rated parameters and six patient-rated parameters, with each parameter scored from 1 to 10.Observer ScalePatient ScaleParameterScore (1~10)ParameterScore (1~10)VascularityPainColorPruritusThicknessColorSurface RoughnessThicknessPliaibilityPlasticitySurface AreaAppearance Table 1Scar Assessment Using the Patient and Observer Scar Assessment Scale (POSAS)Table summarizing the Patient and Observer Scar Assessment Scale (POSAS), including six observer-rated parameters and six patient-rated parameters, with each parameter scored from 1 to 10.Observer ScalePatient ScaleParameterScore (1~10)ParameterScore (1~10)VascularityPainColorPruritusThicknessColorSurface RoughnessThicknessPliaibilityPlasticitySurface AreaAppearance Scar Assessment Using the Patient and Observer Scar Assessment Scale (POSAS) Observer scale: Two dermatologists who were not involved in the treatment scored the vascularity, pigmentation, thickness, flatness, and softness of scars based on standardized photographs, with a total score range of 6-60 points. Patient scale: The patients scored scar pain, itching, color, hardness, thickness, and irregularity based on their perceived feelings, with a total score range of 6–60 points. Both scales were scored as higher scores and worse scar conditions. Secondary efficacy indicators: A four-part efficacy grade assessment was used. The two dermatologists blindly evaluated the overall improvement of scars based on high-definition photos captured before and after treatment, and the evaluation criteria were as follows: An improvement of >75% was considered significant. An improvement of 51–75% was considered effective. An improvement of 26–50% was considered general. An improvement of <25% was considered ineffective. The total response rate was defined as the sum of the proportion of patients with significant improvement, effective improvement, and general improvement. Safety assessment All adverse reactions that occurred during treatment and follow-up, including immediate postoperative reactions (pain, erythema, and edema), delayed reactions (acne-like rash, pustules, exudation, and infection), and long-term complications (PIH, hypopigmentation, and scar hyperplasia or exacerbation), were recorded. The severity and outcomes of these reactions were assessed. Follow-up plan: The main efficacy was evaluated 3 months after the last treatment. In addition, the patients were followed up for 6 months after the end of treatment to assess the stability of efficacy, recurrence rate, and long-term satisfaction. Statistical Analysis The Statistical Package for the Social Sciences (SPSS; version 25.0) software was used for statistical analysis. Continuous data were expressed as the mean ± standard deviation (x ± s), and the paired t-test was used for comparison between groups. Statistics were expressed as a percentage (%). A P-value of <0.05 indicated statistically significant differences. Results Baseline Clinical Data and Treatment Overview This study included 34 patients, including 10 men and 24 women, with a mean age of 32.97 ± 9.30 years. The scar duration ranged from 1 to 12 years, with an average of 5.4 ± 2.8 years. With regard to scar etiology, 23 patients had post-acne scars, 6 patients had post-laser treatment scars, 2 patients had post-burn scars, and 3 patients had post-traumatic scars. The number of treatments received by all patients ranged from 3 to 8, with an average of 5.44 ± 1.80 (Table 2). With an increase in the number of treatments, the appearance and microstructure of scars showed significant improvements. Clinical macroscopic photos showed that the degree of scar depression was significantly reduced after treatment, the surface was gradually flattened, and the color of the pigmented area that was originally dark red or dark brown was significantly lightened, resembling the surrounding normal skin tone. Dermatoscopy confirmed these changes. Dense punctate or clumpy pigmentation in the dermis and disturbed vascular structures were visible before treatment. However, after treatment, pigmentation was significantly reduced or disappeared, the kurtosis and crest texture gradually recovered, and the unit alignment of the follicular sebaceous glands tended to normalize, with only a mild postinflammatory erythema response (Figures 1–4).Table 2Clinical Characteristics of Patients with Hyperpigmented ScarsTable summarizing the clinical characteristics of 34 patients with hyperpigmented scars, including age, scar duration, sex, etiology, and number of treatment sessions.VariablesCharacteristicsTotal cases34Age (y)32.97± 9.30 years (range 19–56 years)Duration (y)5.4± 2.8 yearsRange(range 1–12 years)Sex Male/female10 (29.4) / 24 (70.6)Etiology Acne23 (67.6) Post-laser therapy6 (17.6) Trauma3 (8.8) Burns2 (5.9)Number of treatments5.44± 1.80 timesrange(range 3.00–8.00 times) Figure 1Clinical changes in a laser-induced burn scar of the right lower eyelid treated with the artificial fractional CO2 laser mode combined with moist wound healing (Case 1, two-dimensional clinical photographs). (A) Before treatment: Healed burn scar with mild atrophy (depression) and marked hyperpigmentation. (B) Immediately after treatment: Clinical endpoint after laser treatment. (C) Immediately after treatment: Application of a topical moisturizing ointment to maintain a moist wound-healing environment. (D) Interim follow-up: Improvement in scar depression and pigmentation. (E) Retreatment: Artificial fractional CO2 laser mode combined with deep mode. (F) Final follow-up: Hyperpigmentation was largely resolved, with mild residual depression. Treatment parameters: Artificial fractional CO2 laser mode (1.0 (W) combined with deep mode (energy, 10.0–12.5 mJ/cm2; density, 5%; spot size, 6–10 mm).Composite clinical photograph with six close-ups of a right lower eyelid scar across time points. Figure 2Dermoscopic changes in a laser-induced burn scar of the right lower eyelid treated with the artificial fractional CO2 laser mode combined with moist wound healing (Case 1). (A) Baseline, natural light: Dark-brown pigmentation. (B) Interim follow-up, natural light: Reduced pigmentation compared with baseline. (C) Final visit, natural light: No visible pigmentation but a mild inflammatory response. (D) Baseline, polarized light: Deep-brown pigmentation visible in the dermis. (E) Interim follow-up, polarized light: Reduced pigmentation compared with baseline. (F) Final visit, polarized light: No visible pigmentation but a mild inflammatory response.A composite clinical photograph with six labeled close-up skin images, A through F, each with a measurement scale. Figure 3Clinical changes in a laser-induced burn scar of on the left side of the face (treated with the artificial fractional CO2 laser mode combined with moist wound healing (Case 2, two-dimensional clinical photographs). (A) Before treatment: Round, hyperpigmented burn scar. (B) Immediately after treatment: Clinical endpoint after laser treatment. (C) Immediately after treatment: Application of a topical moisturizing ointment to maintain a moist wound-healing environment. (D) Early follow-up: The scar was flatter and pigmentation had faded compared with baseline. (E) Retreatment: Artificial fractional mode was applied to the central depression; deep and superficial modes were applied to the peripheral area. (F) Final follow-up: The scar was effectively flattened, and skin color had substantially normalized. Treatment parameters: Artificial fractional CO2 mode (1.0 (W) for the depressed area, combined with deep mode (energy, 10.0–12.5 mJ/cm2; density, 5%) and superficial mode (energy, 125 mJ/cm2) for pigmentation.Composite clinical image with six photographs showing changes in a pigmented burn scar on the left side of the face at different treatment and follow-up stages. The scar is initially round, hyperpigmented, and depressed; subsequent images show laser treatment, moist wound care, progressive flattening and fading of pigmentation, and substantial normalization of skin color at the final follow-up. Figure 4Dermoscopic changes in a laser-induced burn scar of the left lower eyelid treated with the artificial fractional CO2 laser mode combined with moist wound healing (Case 2). (A) Baseline, natural light: Light-brown pigmentation; epidermal texture similar to that of the surrounding skin. (B) Early follow-up, natural light: No substantial change in pigmentation. (C) Final visit, natural light: Marked reduction in epidermal and dermal pigmentation. (D) Baseline, polarized light: Light-brown dermal pigmentation; hair follicular units similar to those of the surrounding skin. (E) Early follow-up, polarized light: No substantial change in pigmentation. (F) Final visit, polarized light: Marked reduction in epidermal and dermal pigmentation.Composite dermoscopic image with six close-up views showing changes in pigmentation of a scar on the left side of the face at baseline, early follow-up, and final follow-up under natural and polarized light. Pigmentation is visible at baseline and becomes markedly reduced by the final visit. Table 2Clinical Characteristics of Patients with Hyperpigmented ScarsTable summarizing the clinical characteristics of 34 patients with hyperpigmented scars, including age, scar duration, sex, etiology, and number of treatment sessions.VariablesCharacteristicsTotal cases34Age (y)32.97± 9.30 years (range 19–56 years)Duration (y)5.4± 2.8 yearsRange(range 1–12 years)Sex Male/female10 (29.4) / 24 (70.6)Etiology Acne23 (67.6) Post-laser therapy6 (17.6) Trauma3 (8.8) Burns2 (5.9)Number of treatments5.44± 1.80 timesrange(range 3.00–8.00 times) Clinical Characteristics of Patients with Hyperpigmented Scars Clinical changes in a laser-induced burn scar of the right lower eyelid treated with the artificial fractional CO2 laser mode combined with moist wound healing (Case 1, two-dimensional clinical photographs). (A) Before treatment: Healed burn scar with mild atrophy (depression) and marked hyperpigmentation. (B) Immediately after treatment: Clinical endpoint after laser treatment. (C) Immediately after treatment: Application of a topical moisturizing ointment to maintain a moist wound-healing environment. (D) Interim follow-up: Improvement in scar depression and pigmentation. (E) Retreatment: Artificial fractional CO2 laser mode combined with deep mode. (F) Final follow-up: Hyperpigmentation was largely resolved, with mild residual depression. Treatment parameters: Artificial fractional CO2 laser mode (1.0 (W) combined with deep mode (energy, 10.0–12.5 mJ/cm2; density, 5%; spot size, 6–10 mm). Dermoscopic changes in a laser-induced burn scar of the right lower eyelid treated with the artificial fractional CO2 laser mode combined with moist wound healing (Case 1). (A) Baseline, natural light: Dark-brown pigmentation. (B) Interim follow-up, natural light: Reduced pigmentation compared with baseline. (C) Final visit, natural light: No visible pigmentation but a mild inflammatory response. (D) Baseline, polarized light: Deep-brown pigmentation visible in the dermis. (E) Interim follow-up, polarized light: Reduced pigmentation compared with baseline. (F) Final visit, polarized light: No visible pigmentation but a mild inflammatory response. Clinical changes in a laser-induced burn scar of on the left side of the face (treated with the artificial fractional CO2 laser mode combined with moist wound healing (Case 2, two-dimensional clinical photographs). (A) Before treatment: Round, hyperpigmented burn scar. (B) Immediately after treatment: Clinical endpoint after laser treatment. (C) Immediately after treatment: Application of a topical moisturizing ointment to maintain a moist wound-healing environment. (D) Early follow-up: The scar was flatter and pigmentation had faded compared with baseline. (E) Retreatment: Artificial fractional mode was applied to the central depression; deep and superficial modes were applied to the peripheral area. (F) Final follow-up: The scar was effectively flattened, and skin color had substantially normalized. Treatment parameters: Artificial fractional CO2 mode (1.0 (W) for the depressed area, combined with deep mode (energy, 10.0–12.5 mJ/cm2; density, 5%) and superficial mode (energy, 125 mJ/cm2) for pigmentation. Dermoscopic changes in a laser-induced burn scar of the left lower eyelid treated with the artificial fractional CO2 laser mode combined with moist wound healing (Case 2). (A) Baseline, natural light: Light-brown pigmentation; epidermal texture similar to that of the surrounding skin. (B) Early follow-up, natural light: No substantial change in pigmentation. (C) Final visit, natural light: Marked reduction in epidermal and dermal pigmentation. (D) Baseline, polarized light: Light-brown dermal pigmentation; hair follicular units similar to those of the surrounding skin. (E) Early follow-up, polarized light: No substantial change in pigmentation. (F) Final visit, polarized light: Marked reduction in epidermal and dermal pigmentation. Clinical Efficacy Analysis POSAS Score Improvement All patients showed a statistically significant decrease in POSAS scores at the 3-month follow-up after the last treatment compared to those before treatment (Table 3 and Table 4). The total score on the observer scale decreased from 42.71 ± 2.49 to 16.71 ± 2.04 (Figure 5), with particularly significant reductions in the scores of the vascularity and pigmentation dimensions. The total score on the patient scale decreased from 41.26 ± 2.76 to 16.85 ± 2.31 (Figure 6), indicating that the perceived pain, itching, and scar color improved significantly. The total POSAS score decreased from 83.97 ± 4.16 before treatment to 33.56 ± 3.27 after treatment, with the difference being statistically significant (P < 0.0001) (Figure 7).Table 3Analysis of Observer Scale Scores Before and After TreatmentTable comparing six observer scale scores before and after treatment. Scores for vascularity, color, thickness, surface roughness, pliability, and surface area were lower after treatment than before treatment.IndicatorsBefore TreatmentAfter all TreatmentsBefore Treatment vs After All TreatmentstpVascularity6.38±1.182.38±0.4918.2330.001Color8.06±0.853.09±0.8722.8760.001Thickness8.03±0.763.12±0.8826.4350.001Surface Roughness6.06±0.852.53±0.5119.5760.001Pliaibility7.24±1.022.53±0.5124.0220.001Surface Area6.94±0.813.06±0.7819.2730.001 Table 4Analysis of Patient Scale Scores Before and After TreatmentTable comparing six patient scale scores before and after treatment. Scores for pain, pruritus, color, thickness, plasticity, and appearance were lower after treatment than before treatment.IndicatorsBefore TreatmentAfter all TreatmentsBefore Treatment vs After All TreatmentstpPain6.03±0.762.56±0.5020.4010.001Pruritus6.38±1.161.82±0.7221.5130.001Color7.47±1.212.97±0.7618.4840.001Thickness6.94±0.813.00±0.8521.4490.001Plasticity7.53±1.023.56±0.5020.7790.001Appearance6.91±0.832.94±0.8517.9380.001 Figure 5Total observer scale scores of all patients before and after treatment.A bar graph showing observer scale total score before treatment and after treatment.Note: ****P < 0.0001. Figure 6Total patient scale scores of all patients before and after treatment.A bar graph showing patient scale total score before treatment and after treatment.Note: ****P < 0.0001. Figure 7Total Patient and Observer Scar Assessment Scale (POSAS) scores of all patients before and after treatment.A bar graph showing POSAS total score before treatment and after treatment.Note: ****P < 0.0001. Table 3Analysis of Observer Scale Scores Before and After TreatmentTable comparing six observer scale scores before and after treatment. Scores for vascularity, color, thickness, surface roughness, pliability, and surface area were lower after treatment than before treatment.IndicatorsBefore TreatmentAfter all TreatmentsBefore Treatment vs After All TreatmentstpVascularity6.38±1.182.38±0.4918.2330.001Color8.06±0.853.09±0.8722.8760.001Thickness8.03±0.763.12±0.8826.4350.001Surface Roughness6.06±0.852.53±0.5119.5760.001Pliaibility7.24±1.022.53±0.5124.0220.001Surface Area6.94±0.813.06±0.7819.2730.001 Analysis of Observer Scale Scores Before and After Treatment Table 4Analysis of Patient Scale Scores Before and After TreatmentTable comparing six patient scale scores before and after treatment. Scores for pain, pruritus, color, thickness, plasticity, and appearance were lower after treatment than before treatment.IndicatorsBefore TreatmentAfter all TreatmentsBefore Treatment vs After All TreatmentstpPain6.03±0.762.56±0.5020.4010.001Pruritus6.38±1.161.82±0.7221.5130.001Color7.47±1.212.97±0.7618.4840.001Thickness6.94±0.813.00±0.8521.4490.001Plasticity7.53±1.023.56±0.5020.7790.001Appearance6.91±0.832.94±0.8517.9380.001 Analysis of Patient Scale Scores Before and After Treatment Total observer scale scores of all patients before and after treatment. Total patient scale scores of all patients before and after treatment. Total Patient and Observer Scar Assessment Scale (POSAS) scores of all patients before and after treatment. Four-Part Method for Efficacy Rating A total of 10 (29.41%) patients showed significant improvement, 21 (61.76%) patients showed effective improvement, and 3 (8.82%) patients showed general improvement. The overall effective rate was 100.00% (Table 5).Table 5Overall Improvement in Hyperpigmented ScarsTable showing the distribution of overall improvement in hyperpigmented scars among 34 patients: 10 patients had greater than 75% improvement, 21 had 51–75% improvement, 3 had 26–50% improvement, and none had 25% or less improvement.Cases (%)Improvement (%)Total≤250 (0.00)26~503 (8.82)51~7521 (61.76)>7510 (29.41) Table 5Overall Improvement in Hyperpigmented ScarsTable showing the distribution of overall improvement in hyperpigmented scars among 34 patients: 10 patients had greater than 75% improvement, 21 had 51–75% improvement, 3 had 26–50% improvement, and none had 25% or less improvement.Cases (%)Improvement (%)Total≤250 (0.00)26~503 (8.82)51~7521 (61.76)>7510 (29.41) Overall Improvement in Hyperpigmented Scars Safety and Tolerance The combination regimen was generally safe and well-tolerated throughout the treatment and follow-up. As anticipated, all patients developed mild-to-moderate erythema and edema immediately after laser therapy, which spontaneously resolved within 3–7 days. Among the 34 patients, 3 (8.82%) patients developed mild, focal PIH after the first treatment, which did not require special intervention and completely resolved at the 3-month follow-up. One patient (2.94%) had scattered acne-like rashes during moist healing, which were controlled after the frequency of care was adjusted. No serious adverse reactions occurred. In the satisfaction survey after the end of treatment,20 (58.82%) patients were extremely satisfied, 11 (32.35%) patients were very satisfied, and the overall satisfaction (including extremely satisfied and very satisfied) rate was 91.17%(Table 6).Table 6Patient SatisfactionTable showing patient satisfaction after treatment: 20 patients (58.82%) were extremely satisfied, 11 (32.35%) were very satisfied, 3 (8.82%) were slightly satisfied, and none were not satisfied.Cases (%)SatisfactionTotalExtremely satisfied20 (58.82)Very satisfied11 (32.35)Slightly satisfied3 (8.82)Not satisfied0 (0.00) Table 6Patient SatisfactionTable showing patient satisfaction after treatment: 20 patients (58.82%) were extremely satisfied, 11 (32.35%) were very satisfied, 3 (8.82%) were slightly satisfied, and none were not satisfied.Cases (%)SatisfactionTotalExtremely satisfied20 (58.82)Very satisfied11 (32.35)Slightly satisfied3 (8.82)Not satisfied0 (0.00) Patient Satisfaction Discussion Pigmented scars result from the combined effects of aberrant scar remodeling and persistent inflammation, which lead to disturbances in melanin metabolism. After skin injury, inflammatory mediators and growth factors released by keratinocytes and immune cells continuously stimulate melanocyte activity, increasing melanin synthesis and causing abnormal melanin deposition in both the epidermis and dermis.5–7 Therefore, effective treatment of pigmented scars requires not only reducing hyperpigmentation but also simultaneously improving scar structure and the local inflammatory microenvironment. Conventional pigment-targeted therapies, such as hydroquinone, retinoids, and chemical peels, can reduce superficial hyperpigmentation to some extent; however, they have limited efficacy in addressing structural abnormalities, such as depressed, hypertrophic, or contracted scars.8,9 Ablative fractional CO2 laser therapy creates microthermal zones that remove abnormal scar tissue and stimulate collagen remodeling, thereby improving scar thickness, contour, and surface texture.10 However, the acute inflammatory response triggered by laser treatment may induce or exacerbate PIH, which is of particular concern in patients with darker skin tones. Therefore, appropriate postoperative wound management is essential for balancing scar remodeling efficacy with pigmentary safety. Moist wound healing can help address this issue. Winter first reported that wounds maintained in a moist environment re-epithelialized significantly faster than those left to dry and form a crust.11 In this study, erythromycin ophthalmic ointment was selected as the moist wound care agent, primarily because its liquid paraffin and petrolatum base forms an occlusive film over the wound surface, reducing water loss and maintaining a suitably moist environment. The ophthalmic ointment formulation is also suitable for repeated application on the face and the sensitive periorbital area, while the erythromycin component provides localized antimicrobial protection during the early postoperative period. In addition, its low cost and ready availability facilitate frequent application by patients and improve treatment adherence. A randomized controlled trial found that fusidic acid ointment and plain petrolatum yielded similar wound healing outcomes after electrosurgery, suggesting that the occlusive and moisture-retaining properties of the ointment base are a key factor in promoting healing.12 Therefore, this study evaluated a complete postoperative moist wound healing regimen rather than the therapeutic effect of erythromycin alone. A moist environment prevents premature wound desiccation and crusting, promotes keratinocyte migration, and preserves wound exudate rich in various growth factors, thereby supporting cell proliferation and tissue remodeling.13,14 Studies have shown that moist wound care after fractional CO2 laser therapy shortens re-epithelialization time, reduces postoperative erythema and edema, and alleviates pain and pruritus. Based on this rationale, this study used individualized, multimodal fractional CO2 laser therapy combined with a standardized moist wound healing regimen to treat Asian patients with facial pigmented scars. After treatment, the total POSAS score significantly decreased from 83.97 ± 4.16 to 33.56 ± 3.27 (P < 0.0001), with improvements observed in vascularity, pigmentation, thickness, pain, pruritus, and color. Standardized clinical photography and dermoscopy revealed that scar contours became flatter and hyperpigmentation was markedly reduced. Furthermore, 91.17% of the patients reported being extremely satisfied or very satisfied with the treatment. The overall safety profile was favorable, with only three patients (8.82%) developing mild, localized PIH, which resolved spontaneously within 3 months. No severe infections, permanent hypopigmentation, or scar worsening occurred. Although fractional CO2 laser therapy and moist wound healing are not novel approaches, the clinical value of this study lies in the integration of these established therapeutic approaches for the treatment of Asian patients with facial pigmented scars, a condition characterized by etiological and morphological heterogeneity. The treatment protocol simultaneously addressed scar structure, pigmentary changes, patient-reported symptoms, satisfaction, and pigment-related safety. Consistent improvements were observed across standardized photography, dermoscopy, observer scale scores, patient scale scores, and satisfaction ratings, providing clinically meaningful evidence for the feasibility of this combined strategy in real-world clinical settings. This study was a single-center retrospective analysis with a limited sample size and no concurrent control group; therefore, the observed therapeutic effects cannot be individually attributed to the fractional CO2 laser therapy, ointment base, or erythromycin component. In addition, objective quantitative measures, such as colorimetry, skin elasticity assessment, and high-frequency ultrasound assessment, were not included in the available data. Future prospective controlled studies with larger sample sizes and longer follow-up durations are warranted, with a particular focus on Asian and other darker-skinned populations, the inclusion of parallel comparison groups using different postoperative ointments, and the incorporation of objective metrics to quantify changes in pigmentation and scar architecture. Further investigation into inflammatory and pigment-related pathways, such as IL-6, TNF-α, MITF, and TYR pathways, may help elucidate the potential mechanisms through which moist wound healing facilitates tissue repair while maintaining pigment homeostasis. Conclusion This retrospective study showed clinically meaningful improvements in facial pigmented scars after individualized fractional CO2 laser therapy combined with erythromycin ophthalmic ointment–based moist wound healing. After treatment, both clinician- and patient-reported POSAS scores improved substantially, patient satisfaction was high, and adverse events were mild and self-limited. These findings support the clinical utility of this integrated approach for patients who require both scar remodeling and pigment management, particularly Asian patients at risk for PIH.